Statistics

Total Visits

Views
Weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: Preliminary results of CABASEM-SOGUG phase II trial.52

Select a period of time:

Number of views in the range

Views
Weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: Preliminary results of CABASEM-SOGUG phase II trial.16

Views

Views
June 20250
July 202510
August 20251
September 20251
October 20252
November 20250
December 20252
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States5
Brazil4
South Africa2
Argentina1
Canada1
Spain1
Italy1
Venezuela1
 

Top cities views

Views
Dallas2
Cape Town1
Casilda1
Contagem1
Klerksdorp1
Madrid1
Manteca1
Maracay1
Padova1
Passo Fundo1